Filing excerpt
On September 23, 2026, Bio-Techne issued a press release announcing Bio-Techne shareholders’ approval of the Merger Agreement Proposal.
sec.gov/Archives/edgar/data/842023/000114036126037450/ef20082601_8k.htmRead the full source
Bio-Techne8-K: Acquisition announced
Bio-Techne shareholders approve acquisition by Merck KGaA, Darmstadt, Germany
What happened
Shareholder approval moves the acquisition by Merck KGaA closer to completion, intensifying the need for operational and IT integration.
Source
Other signals in this filing (3)
- RestructuringBio-Techne shareholders approve merger with Merck KGaA, triggering a massive post-merger integration initiative.Restructuring
- Restructuring chargeBio-Techne shareholders approve merger with Merck KGaA, triggering major operational integration.Restructuring charge
- Customer churnBio-Techne flags risk of customer loss and business disruption following merger approval.Customer churn
Extracted by Autobound
From the Signal API record- Signal
- 8-K: Acquisition announced
What this signalsIntegration work after a deal often opens needs for new systems and services.
- Form
- 8-K
- Filed
- Sep 23, 2026
More from Bio-Techne
- PatentsBio-Techne Corporation's patent output is steady: 1 grant in the past year, 0 in the past 30 days.Patents
- New locationBio-Techne Opens New Customer Experience Centre in Düsseldorf, Strengthening Scientific Exchange and Collaboration with Customers in EuropeNew location
- CertificationBio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate GoalsCertification
- 10-KBio-Techne completed acquisition of spatial biology firm Lunaphore in fiscal 202410-K
- GlassdoorEmployees report lack of growth opportunities and encouragementGlassdoor
- LinkedInBio-Techne reports improved Q4 and FY26 performance, awaiting acquisition by Merck KGaA.LinkedIn
More 8-K signals at other companies
- SEC 8-K4D Molecular Therapeutics, Inc.4D Molecular Therapeutics initiates Phase 3 trial directly challenging competitor drug aflibercept.SEC 8-K
- SEC 8-KAdeia Inc.Adeia Inc. appoints new CEO Dipti Vachani, effective October 12, 2026, replacing outgoing CEO Paul E. Davis.SEC 8-K
- SEC 8-KAdicet Bio, Inc.Adicet Bio launching pivotal clinical trial in Q4 2026 after positive Phase 1 data for Prula-cel.SEC 8-K
The full record
From the Signal API recordDetails
- CIK
- 842023
- Accession number
- 0001140361-26-037450
- Timeframe
- Current quarter
- Filing year
- 2026
- Why it matters
- Integration needs coming
- Signal category
- Strategic
Extraction
- Confidence
- High
- Relevance
- 90%
- Sentiment
- Neutral
- Detected
- Sep 29, 2026
- signal_type
sec-8k- signal_subtype
acquisitionAnnounced
Use this data
Get every 8-K signal for Bio-Techne and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bio-Techne this week?”
Send it to your own tools
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/5c949e00-8175-45d6-8358-02e788580983 returns this record as JSON. POST /v1/companies/enrich returns every signal for bio-techne.com.
{
"signal_id": "5c949e00-8175-45d6-8358-02e788580983",
"signal_type": "sec-8k",
"signal_subtype": "acquisitionAnnounced",
"detected_at": "2026-09-29T08:10:52.602+00:00",
"company": {
"name": "Bio-Techne",
"domain": "bio-techne.com"
},
"data": {
"detail": "Shareholder approval moves the acquisition by Merck KGaA closer to completion, intensifying the need for operational and IT integration. This creates significant opportunities for vendors specializing in M&A integration, system consolidation, and change management as the companies look to merge potentially disparate technology stacks and business processes.",
"metrics": {
"timeframe": "current_quarter"
},
"summary": "Bio-Techne shareholders approve acquisition by Merck KGaA, Darmstadt, Germany",
"excerpts": "On September 23, 2026, Bio-Techne issued a press release announcing Bio-Techne shareholders’ approval of the Merger Agreement Proposal.",
"relevance": 0.9,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/842023/000114036126037450/ef20082601_8k.htm",
"filing_date": "2026-09-23",
"filing_year": 2026,
"sales_relevance": "Integration needs coming",
"signal_category": "strategic"
}
}
curl https://signals.autobound.ai/v1/signals/5c949e00-8175-45d6-8358-02e788580983 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bio-techne.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.